BIOMAT Database Logo BIOMAT Database Logo

Potential Therapeutic Targets and Promising Agents for Combating NAFLD. 2022

Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Department of Pharmacology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.

Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is a growing cause of liver cirrhosis and liver cancer worldwide because of the global increases in obesity, dyslipidemia, hypertension, and type 2 diabetes mellitus. Contrary to the advancements in therapies for viral hepatitis, effective treatments remain unestablished for patients with NAFLD. NAFLD, including NASH, is characterized by steatosis, inflammation, hepatic necrosis, and fibrosis. Despite our understanding of its pathophysiology, there are currently no effective treatments for NAFLD. In this review, we provide an update on the known pathophysiological mechanisms involved in the development of NAFLD and the role of hepatic stellate cells, and summarize the potential therapeutic agents, including natural products, for NAFLD.

UI MeSH Term Description Entries

Related Publications

Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
July 2020, British journal of pharmacology,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Potential therapeutic targets for combating Mycoplasma genitalium.
January 2023, 3 Biotech,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Curcumin Nanoparticles as Promising Therapeutic Agents for Drug Targets.
August 2021, Molecules (Basel, Switzerland),
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Roles of PPARs in NAFLD: potential therapeutic targets.
May 2012, Biochimica et biophysica acta,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Potential Epigenetic Targets for Combating Alzheimer's Disease.
January 2021, Mini reviews in medicinal chemistry,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
New antiherpesvirus agents. Their targets and therapeutic potential.
July 1996, Drugs,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Ferroptosis in ulcerative colitis: Potential mechanisms and promising therapeutic targets.
May 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
September 2020, Life sciences,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Promising therapeutic targets for antileishmanial drugs.
August 2002, Expert opinion on therapeutic targets,
Atsushi Umemura, and Seita Kataoka, and Keiichiro Okuda, and Yuya Seko, and Kanji Yamaguchi, and Michihisa Moriguchi, and Takeshi Okanoue, and Yoshito Itoh
Promising therapeutic agents for sepsis.
January 2007, Trends in microbiology,
Copied contents to your clipboard!